Scion Life Sciences, an affiliate of the health care investment firm Petrichor, launched on 7 February with two friends and former Apple Tree Partners (ATP) colleagues – Scion co-founders and managing partners Sam Hall and Aaron Kantoff – at the helm. The new venture capital firm raised $310m for its inaugural fund, which it will use to build and fund new drug developers as it establishes an initial portfolio of six to seven biopharmaceutical companies.
“We actually started with a $250m target and had a really positive experience … and the interest and momentum enabled...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?